MarketPR
The United Kingdom's approval of Eli Lilly's oral weight-loss pill Foundayo (LLY) is the drug's first regulatory clearance in Europe, shifting the Lilly-Novo Nordisk competition beyond the U.S.
Novo Nordisk's Wegovy had already established a European presence before this decision.
The next milestone for the LLY setup is commercial launch timing in Britain and whether Lilly files for approval in additional European markets. A first European foothold for Foundayo Foundayo is a pill.
clearance is its first regulatory approval outside the United States. That geography is material: the weight-loss drug competition between Lilly and Novo Nordisk has until now played out primarily in the U.S.
Keep reading